

## Biopharmagen Corp., Fangzhou Suzhou

Clinical-grade cell growth factors & Human stem cell culture medium

Innovative

Scientific

Reliable

Munimuni



WeChat Official Account



Biopharmagen Corp., Fangzhou Suzhou www.biopharmagen.com Tel: +86-18913198920/+86-18913198927 Email: research@biopharmagen.com



## Recombinant Growth factors

For over 30 years, we have delivered cuttingedge recombinant protein technologies, specializing in:

- ✓ Advanced refolding
- ✓ High-efficient purification
- ✓ Clinical-grade biomedical applications



## Cytokines are newly launched!

More products coming soon...

## **Core Advantages**

### Three Decades of Excellence in Recombinant Protein Production

For 30 years, we have been at the forefront of:

Clinical-grade Protein Purity – Mature, stable processes delivering
>98% purity with preserved bioactivity.

GMP-Compliant Manufacturing – China's first internationalstandard GMP biologics line, guaranteeing batch-to-batch consistency for therapeutic applications.

Fridging Academia & Industry – Strategic alliances with top-tier research institutes to accelerate breakthroughs in biologics, diagnostics, and cell therapy.







## **Product Catalog**

Catalog	Name	Specifications/Price					
C001	recombinant human IL-6	10 µg	\$ 66	50 µg	\$ 250	100 µg	\$ 375
C002	recombinant human IL-3	10 µg	\$ 108	50 µg	\$ 335	100 µg	\$ 418
C003	recombinant human SCF	10 µg	\$ 98	50 µg	\$ 208	100 µg	\$ 383
C004	recombinant human FLT3L	10 µg	\$ 98	50 µg	\$ 208	100 µg	\$ 383
C005	recombinant human TPO	10 µg	\$ 80	50 µg	\$ 300	100 µg	\$ 458
C006	recombinant human GM-CSF	10 µg	\$ 80	50 µg	\$ 368	100 µg	\$ 533
C007	recombinant human G-CSF	10 µg	\$ 158	50 µg	\$ 398	100 µg	\$ 533

More premium cytokines and bioactive enzymes coming soon...

## **Product Features**

Premium Bioactivity	Low Endotoxin	Exogenous-free		
Potency: ED <sub>50</sub> < 0.1 ng/mL	endotoxin <0.1 ΕU/μg, by LAL	no exogenous genes or proteins were introduced		
		Ready To Use		
Clinical-grade Purity	High Stability	Ready To Use		

Biopharmagen Corp., Fangzhou Suzhou Email: research@biopharmagen.com Tel: +86-18913198920/+86-18913198927 Address: Room 408-410, Building 2, Hengchuang Technology Park, 128 Jinling East Road, Weiting, Suzhou Industrial Park www.biopharmagen.com





## Clinical-Grade Human Hematopoietic Stem Cell Xeno-free Expansion Kit

#### 20 Years Pioneering Stem Cell Differentiation Technologies Proprietary Platform | Peer-Validated Excellence



#### Clinical-Grade Human Hematopoietic Stem Cell Xeno-free Expansion Kit

✓ Universal Compatibility – Optimized for UCB, BM, and mPB-derived HSCs with >50-fold expansion efficiency

✓ Xeno-Free & Feeder-Free – Contains precisely balanced:

Clinical-grade and optimized cytokine cocktail Metabolic regulators

✓ Functional Integrity – Expanded HSCs retain: Engraftment capacity & Multilineage potential

Catalog	Name	Specifications/Price		
M001	Human Stem Cell Basal Medium + Nutritional Supplement	100 mL	\$ 168	
CC01	CD34+ Expansion Supplement	1000 ×	\$ 133	
SC01	CD34+ Differentiation Inhibitors	1000 ×	\$ 88	

(verified in non-human primate model)

\*Freedom to combine, power to customize

### Human Hematopoietic Stem Cells Cultured in vitro





Day 6



WeChat Official Account



Biopharmagen Corp., Fangzhou Suzhou Email: research@biopharmagen.com Tel: +86-18913198920/+86-18913198927 Address: Room 408-410, Building 2, Hengchuang Technology Park, 128 Jinling East Road, Weiting, Suzhou Industrial Park

## ≻Highlights

- ✓ Serum-Free: Eliminates batch variability and reduces pathogen contamination risks.
- ✓ Stemness: Significantly suppresses spontaneous differentiation, maintains >90% CD34+ purity and multipotency.
- ✓ **Ready-to-Use:** Presterilized, pre-mixed formulation for streamlined workflow.
- ✓ **Regulatory-Compliance:** Suitable for research, drug screening, and cell therapy development.

#### ≻Data Support



- 1. Wang L, Guan X, Wang H, et al. A small-molecule/cytokine combination enhances hematopoietic stem cell proliferation via inhibition of cell differentiation [J].Stem Cell Research & Therapy, 2019.
- Zhang Y, Shen B, Guan X, et al.Safety and efficacy of ex vivo expanded CD34+ stem cells in murine and primate models[J].Stem Cell Research & Therapy, 2019.
- Jiang Yongping. High-Efficiency Ex Vivo Expansion Medium for Human Hematopoietic Stem Cells : CN201410066574.9 [P]. CN201410066574.9.

#### ≻ Choose Us

Animal Component-Free: Fully defined, xeno-free formulation eliminates immune rejection and viral contamination.

**High-Efficiency & Stable Expansion:** Supports robust proliferation of HSCs derived from umbilical cord blood (UCB), bone marrow (BM), and mobilized peripheral blood (mPB) within short-term culture.

**Customized Solutions:** Tailored culture optimization services available for specific research or clinical applications.

Biopharmagen Corp., Fangzhou Suzhou Email: research@biopharmagen.com Tel: +86-18913198920/+86-18913198927 Address: Room 408-410, Building 2, Hengchuang Technology Park, 128 Jinling East Road, Weiting, Suzhou Industrial Park www.biopharmagen.com







## Clinical-Grade Megakaryocyte/Platelet Directional Differentiation Kit

#### 20 Years Pioneering Stem Cell Differentiation Technologies Proprietary Platform | Peer-Validated Excellence



#### Clinical-Grade Megakaryocyte/Platelet Directional Differentiation Kit

✓ Universal Compatibility – Specifically optimized for UCB, BM, and mPB-derived HSCs to expand and differentiate into megakaryocytes/platelets with high-efficiency

#### ✓ Xeno-Free & Feeder-Free – Contains precisely balanced: Clinical-grade and optimized cytokine cocktail

Metabolic regulators

#### ✓ Functional Integrity

Catalog	Name	Specifications/Price		
M001	Human Stem Cell Basal Medium + Nutritional Supplement	100 mL	\$ 168	
CC02	Megakaryocyte Expansion & Differentiation Supplement 1	1000 ×	\$ 133	*
CC03	Megakaryocyte Expansion & Differentiation Supplement 2	1000 ×	\$ 168	p

#### <sup>\*</sup>Freedom to combine, power to customize

#### > Hematopoietic Stem Cell Directional Differentiate into Megakaryocytes/Platelets



Biopharmagen Corp., Fangzhou Suzhou Email: research@biopharmagen.com Tel: +86-18913198920/+86-18913198927 Address: Room 408-410, Building 2, Hengchuang Technology Park, 128 Jinling East Road, Weiting, Suzhou Industrial Park www.biopharmagen.com





## >Product Highlights

#### **Xeno-Free Formulation High-Efficiency Expansion** Eliminates batch-to-batch variability Optimized cytokine cocktail enables and xeno-contamination risks, scalable production of high-viable ensuring reproducible experiments megakaryocytes Advantages and **Highlights Directional Differentiation Universal Compatibility** Proprietary formulation drives Validated for multiple HSC sources lineage-specific commitment of (UCB/BM/mPB) to address diverse HSCs to megakaryocytes research requirements ► Data Support Day 0 Day 6 Day 6 + 7 105-0.7% 105 16.59 Total cells 0.3% 4.0% 105 14.6% 78.5% 10 CD41a<sup>+</sup> cells Yields per input cel 104 CD42h celle 103 104 104

11 13 days

10

10

10



10<sup>3</sup>

10

0

a: Yields of total cells, CD41a+ cells, and CD42b+ cells per input cryopreserved human cord blood CD34+ cell

b: Representative flow cytometry of CD41a and CD42b cell surface markers on expanded cells

103

102

10

1. Guan X, Qin M, Zhang Y, et al. Safety and Efficacy of Megakaryocytes Induced from Hematopoietic Stem Cells in Murine and Nonhuman Primate Models[J].Stem Cells Transl Med, 2017.

ð

4

- 2. Guan Xin. Large-scale in vitro megakaryocyte production with comprehensive preclinical safety and efficacy evaluation[D]. Peking Union Medical College, 2018
- 3. Jiang Yongping, Guan Xin, Qin Meng, etc. Methods and Systems for Generating Megakaryocytes and Platelets from Human Hematopoietic Stem Cells. 2019

Biopharmagen Corp., Fangzhou Suzhou Email: research@biopharmagen.com Address: Room 408-410, Building 2, Hengchuang Technology Park, 128 Jinling East Road, Weiting, Suzhou Industrial Park www.biopharmagen.com







## **Contact Us**

# Biopharmagen Corp., Fangzhou Suzhou

Biopharmagen Corp., Fangzhou Suzhou www.biopharmagen.com Tel: +86-18913198920/+86-18913198927 Email: research@biopharmagen.com



苏州方舟生物科技有限公司 Biopharmagen Corp.



WeChat Official Account



Made in 2025